mk-7622
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2013 (NCT01852110)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Muscarinic acetylcholine receptor M1ACTIVATOR
CHRM1 activator
- Muscarinic acetylcholine receptor M1POSITIVE ALLOSTERIC MODULATOR
Muscarinic acetylcholine receptor M1 positive allosteric modulator
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(Cc2cc3c(=O)n([C@H]4CCCC[C@@H]4O)cnc3c3ccccc23)cn1- Mol. weight
- 399.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4078588 ↗
Also known as
- mk-7622
- mk-7622
- mk-7622
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01852110 | Phase 2 | Oct 1, 2013 | Merck |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 1 | 1 | 1 | 2013 |
1 organizations
Page 1 / 1